The Conversation (0)
Medigus released its financial results for the third quarter of 2017.
Medigus (NASDAQ:MDGS) released its financial results for the third quarter of 2017.
As quoted in the press release:
“In recent months, we have announced progress across key areas of our development strategy, including broadening the availability of our flagship MUSE™ system with leading multinational distributors,” said Chris Rowland, CEO of Medigus. “We are positioned to enter 2018 with positive momentum as we drive our development and clinical programs forward.”
Financial Results for the Third Quarter 2017:
- Revenues for the three months ended September 30, 2017, were $117,000, a decrease of 14%, compared to the three months ended September 30, 2016
- Research and development expenses for the three months ended September 30, 2017, were $654,000, a decrease of 8%, compared to the three months ended September 30, 2016
- Sales and marketing expenses for the three months ended September 30, 2017, were $159,000, a decrease of 54%, compared to the three months ended September 30, 2016
- General and administrative expenses for the three months ended September 30, 2017, were $490,000, a decrease of 51% compared to the three months ended September 30, 2016
- Operating loss for the three months ended September 30, 2017, was $1,255,000, compared to $1,947,000 in the three months ended September 30, 2016
Click here to read the full press release.
Source: www.marketwired.com
